Morgan Stanley initiates coverage on ARYx Therapeutics (Nasdaq: ARYX) with an Overweight rating.

This article: 68 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE